145 related articles for article (PubMed ID: 26118154)
1. Clinical experience with BIAsp 30: Results from the Bangladesh cohort of the global A1chieve study.
Latif ZA; Pathan MF; Mannan MA; Siddiqui MN; Ashrafuzzaman SM; Rahman MM; Sobhan MJ
Bangladesh Med Res Counc Bull; 2013 Dec; 39(3):93-8. PubMed ID: 26118154
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.
Soewondo P; Pramono RB; Langi YA; Soetedjo NN; Kshanti IA
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S54-9. PubMed ID: 23647720
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Qureshi MS; Shaikh MZ
J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
[TBL] [Abstract][Full Text] [Related]
4. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
Valensi P; Shaban J; Benroubi M; Kawamori R; Borzì V; Shah S; Wenying Y; Prusty V; Hansen JB; Gumprecht J;
Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
Lim-Abrahan MA; Jain AB; Bebakar WM; Seah D; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
Latif ZA; Pathan MF; Siddiqui MN; Sobhan MJ; Rahman MM; Ashrafuzzaman SM
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
[TBL] [Abstract][Full Text] [Related]
7. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
8. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
Mäkelä JK; Schmüser C; Askonen K; Saukkonen T
Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
[TBL] [Abstract][Full Text] [Related]
9. Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.
Chen L; Xing X; Lei M; Liu J; Shi Y; Li P; Qin G; Li C; Li Y; Wang Q; Gao T; Hu L; Wang Y; Yang W
Chin Med J (Engl); 2014; 127(2):208-12. PubMed ID: 24438605
[TBL] [Abstract][Full Text] [Related]
10. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
Farshchi A; Aghili R; Oskuee M; Rashed M; Noshad S; Kebriaeezadeh A; Kia M; Esteghamati A
BMC Endocr Disord; 2016 Jun; 16(1):35. PubMed ID: 27278922
[TBL] [Abstract][Full Text] [Related]
11. Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A1chieve® observational study.
Yang W; Zhuang X; Li Y; Wang Q; Bian R; Shen J; Hammerby E; Yang L
Health Qual Life Outcomes; 2014 Nov; 12():137. PubMed ID: 25424627
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
Lim-Abrahan MA; Yu-Gan S; Jain AB; Sobrepena LM; Racho VA
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
[TBL] [Abstract][Full Text] [Related]
13. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study.
El Naggar NK; Soewondo P; Khamseh ME; Chen JW; Haddad J
Diabetes Res Clin Pract; 2012 Dec; 98(3):408-13. PubMed ID: 23217267
[TBL] [Abstract][Full Text] [Related]
14. 15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.
Liebl A; Mohan V; Yang W; Strojek K; Linjawi S
Drugs R D; 2018 Mar; 18(1):27-39. PubMed ID: 29468559
[TBL] [Abstract][Full Text] [Related]
15. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial).
Trippe BS; Shepherd MD; Coulter FC; Bhargava A; Brett J; Chu PL; Oyer DS
Curr Med Res Opin; 2012 Jul; 28(7):1203-11. PubMed ID: 22509859
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, open-label, non-randomized, non-interventional observational study of safety of treatment initiation with a biphasic insulin aspart.
Wolnik B; Hak L
Expert Opin Drug Saf; 2013 Mar; 12(2):137-44. PubMed ID: 23289795
[TBL] [Abstract][Full Text] [Related]
18. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.
Liebl A; Prusty V; Valensi P; Kawamori R; Christiansen JS; Palmer AJ; Balschmidt P; Ligthelm R; Mohan V
Drugs; 2012 Jul; 72(11):1495-520. PubMed ID: 22818015
[TBL] [Abstract][Full Text] [Related]
19. Initiating therapy or switching to biphasic insulin aspart improves glycaemic control in type 2 diabetes: an Indian experience from the A1chieve study.
Kumar A; Sharma SK; Rajput R; Unnikrishnan AG
J Assoc Physicians India; 2013 Jan; 61(1 Suppl):16-20. PubMed ID: 24482982
[TBL] [Abstract][Full Text] [Related]
20. [Comparison on the efficacy of biphasic insulin aspart 30 and premixed human insulin 30/70 through continuous glucose monitoring system].
Chen SF; Li H
Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Aug; 32(8):827-9. PubMed ID: 22093477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
